Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion description "[We studied the incidences, associations, and prognostic roles of NOTCH1 and SF3B1 mutations (NOTCH1(mut), SF3B1(mut)) as compared with TP53(mut) in fludarabine-refractory chronic lymphocytic leukemia (CLL) patients treated with alemtuzumab in the CLL2H trial.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion evidence source_evidence_literature NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion SIO_000772 23821658 NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion wasDerivedFrom befree-20140225 NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_assertion wasGeneratedBy ECO_0000203 NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.
- befree-20140225 importedOn "2014-02-25" NP683993.RAyGdMt9BIe7Vwo54fJhtLhfSK8LqkB5dd2Fldu-Rq62M130_provenance.